Tesamorelin
Dosage Protocol

Add 3.0 mL of bacteriostatic water to the 10 mg vial, yielding a concentration of approximately 3.33 mg/mL. [5] Inject the water slowly down the vial wall, then gently swirl until dissolved without shaking; vigorous shaking may denature the peptide. [5]

Before reconstitution, refrigerate the lyophilized form at 2–8 °C. Once reconstituted, do not freeze and avoid repeated freeze-thaw cycles; store at 2–8 °C. [5] Use the reconstituted solution within 7 days. [5]

Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH, also called growth hormone-releasing factor). It functions as a GHRH receptor agonist at the pituitary gland, stimulating endogenous growth hormone release rather than providing direct hormone replacement. [4][3]

A systematic review and meta-analysis reported that tesamorelin 2 mg significantly reduced visceral adipose tissue and increased lean body mass in HIV patients on antiretroviral therapy, though discontinuation rates were higher in treatment groups than in controls. [1] A separate pilot study of low-dose tesamorelin (1 mg) found no direct significant changes in cognitive or physical measures, though machine learning analysis suggested potential treatment-related differences in brain regions associated with cognitive function. [2] Reductions in visceral fat have been reported not to persist after discontinuation, suggesting the effects are treatment-dependent. [4]

Tesamorelin is FDA-approved under the brand name EGRIFTA SV for a specific indication: reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy. Approval is limited to this population and does not extend to general weight loss, anti-aging, or athletic performance uses; those uses are off-label. [4] Compounded versions lack the FDA premarket review and quality assurance of the approved EGRIFTA SV product. [4] This section describes what the cited literature reports; it is not a claim of safety or effectiveness for off-label use.